Get the Stockscreener App
1.7709
3.23%
-0.0591
After Hours:
1.89
0.1191
+6.73%
Immuron Limited Adr stock is traded at $1.7709, with a volume of 119.44K.
It is down -3.23% in the last 24 hours and down -5.80% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$1.83
Open:
$1.63
24h Volume:
119.44K
Relative Volume:
4.87
Market Cap:
$413.88M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-3.952
EPS:
-0.4481
Net Cash Flow:
-
1W Performance:
-6.30%
1M Performance:
-5.80%
6M Performance:
-7.12%
1Y Performance:
-23.67%
1-Day Range:
$1.63
$1.95
1-Week Range:
$1.63
$1.95
52-Week Range:
$1.50
$2.87
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.7709 | 10.48M | 2.35M | -2.56M | 0 | -0.4481 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron Letter to Shareholders: Projects Update - GlobeNewswire Inc.
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Markets Insider
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewswire
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire
Immuron Surges On U.S. DoD Funding For Travelan Research By Investing.com - Investing.com Nigeria
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan
Immuron LimitedADR Shares Close the Week 61.5% HigherWeekly Wrap - Nasdaq
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
IMC Stock Price and Chart — ASX:IMC - TradingView
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):